{"title": "Environmental factors associated with human papillomavirus vaccine coverage in adolescents: 2016-2020 analysis", "author": "Luvisaro; Bianca Maria Oliveira; Silva; Thales Philipe Rodrigues da; Tercia Moreira Ribeiro da; Lachtim; Sheila Aparecida Ferreira; Souza; Janaina Fonseca Almeida; Matozinhos; Fernanda Penido", "url": "https://www.scielo.br/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/", "hostname": "scielo.br", "description": "Abstract Objective: to analyze the association between the factors of the social environment and...", "sitename": "Revista Latino-Americana de Enfermagem", "date": "2022-11-25", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Abstract\nObjective:\nto analyze the association between the factors of the social environment and the coverage rates of the human papillomavirus (HPV) vaccine in adolescents, in the State of Minas Gerais, Brazil.\nMethod:\nthis is an epidemiological, ecological study, with panel and trend analysis from 2016 to 2020. The population consisted of adolescents aged 9 to 13 years. The environmental variables were coverage rates, the municipal index of human development, income, education, and longevity; and the rate of violence. The Prais-Winsten autoregression and the panel regression model were used, in addition to the estimate of the mean annual percentage variation.\nResults:\nthe vaccination coverage rates are below the goals recommended by the Ministry of Health for all regions analyzed. Moreover, these rates are associated with factors related to the application of the first dose and to aspects inherent to the social environment, such as the rate of violence.\nConclusion:\nour findings showed that, although tenuous, aspects of the environment, in addition to individual characteristics, provide relevant information to understand the occurrence of health outcomes, since this vaccination campaign presents a strong influence of the environment and age as factors associated with the low rates.\nDescriptors:\nImmunization; Vaccination Coverage; Adolescent; Papillomaviridae; Epidemiology; Regression Analysis\nResumo\nObjetivo:\nanalisar a associa\u00e7\u00e3o entre os fatores do ambiente social e as taxas de cobertura da vacina contra o papilomav\u00edrus humano (HPV) nos adolescentes do estado de Minas Gerais.\nM\u00e9todo:\nestudo epidemiol\u00f3gico, ecol\u00f3gico, com an\u00e1lise em painel e de tend\u00eancia, no per\u00edodo de 2016 a 2020. A popula\u00e7\u00e3o foi composta por adolescentes de 9 a 13 anos. As vari\u00e1veis ambientais foram as taxas de cobertura; o \u00edndice de desenvolvimento humano municipal, de renda, de educa\u00e7\u00e3o e de longevidade; e a taxa de viol\u00eancia. Utilizou-se o modelo autorregressivo de Prais-Winsten, o c\u00e1lculo da varia\u00e7\u00e3o percentual m\u00e9dia anual e a regress\u00e3o em painel.\nResultados:\nas taxas de cobertura da vacina em todas as regi\u00f5es analisadas est\u00e3o abaixo das metas preconizadas pelo Minist\u00e9rio da Sa\u00fade. Ademais, tais taxas est\u00e3o associadas aos fatores relacionados \u00e0 aplica\u00e7\u00e3o da primeira dose e a aspectos inerentes ao ambiente social, como a taxa de viol\u00eancia.\nConclus\u00e3o:\nas evid\u00eancias encontradas demonstraram que, embora t\u00eanues, aspectos do ambiente, al\u00e9m das caracter\u00edsticas individuais, fornecem informa\u00e7\u00f5es relevantes para compreens\u00e3o da ocorr\u00eancia dos desfechos de sa\u00fade, uma vez que para essa vacina temos a forte influ\u00eancia do ambiente e da idade como fatores associados \u00e0 baixa taxa de vacina\u00e7\u00e3o.\nDescritores:\nImuniza\u00e7\u00e3o; Cobertura Vacinal; Adolescentes; Papillomaviridae; Epidemiologia; An\u00e1lise de Regress\u00e3o\nResumen\nObjetivo:\nanalizar la asociaci\u00f3n entre los factores del entorno social y las tasas de cobertura de la vacuna contra el virus del papiloma humano (VPH) en los adolescentes del estado de Minas Gerais.\nM\u00e9todo:\nestudio epidemiol\u00f3gico, ecol\u00f3gico, con an\u00e1lisis de panel y de tendencia, en el per\u00edodo de 2016 a 2020. La poblaci\u00f3n estaba compuesta por adolescentes de 9 a 13 a\u00f1os. Las variables ambientales fueron las tasas de cobertura; el \u00edndice de desarrollo humano municipal, la renta, la educaci\u00f3n y la longevidad, y la tasa de violencia. Se utiliz\u00f3 el modelo autorregresivo de Prais-Winsten, el c\u00e1lculo de la variaci\u00f3n porcentual media anual y la regresi\u00f3n en panel.\nResultados:\nlas tasas de cobertura de la vacuna en todas las regiones analizadas est\u00e1n por debajo de los objetivos recomendados por el Ministerio de Salud. Adem\u00e1s, estas tasas est\u00e1n asociadas a los factores relacionados con la aplicaci\u00f3n de la primera dosis y a aspectos inherentes al entorno social, como la tasa de violencia.\nConclusi\u00f3n:\nlas evidencias encontradas demostraron que, aunque tenues, aspectos del entorno, adem\u00e1s de las caracter\u00edsticas individuales, proporcionan informaciones relevantes para comprensi\u00f3n de la ocurrencia de los resultados de salud, una vez que para esa vacuna tenemos la fuerte influencia del entorno y de la edad como factores asociados a la baja tasa de vacunaci\u00f3n.\nDescriptores:\nInmunizaci\u00f3n; Cobertura de Vacunaci\u00f3n; Adolescentes; Papilomaviridae; Epidemiolog\u00eda; An\u00e1lisis de Regresi\u00f3n\nHighlights:\n(1) The coverage of human papillomavirus vaccination is below the target in Minas Gerais.\n(2) The rates are associated with aspects inherent to the social environment, such as violence.\n(3) The environment provides relevant information for understanding health outcomes.\nIntroduction\nThe human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections in the world11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039\n[https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039). HPV is a virus capable of infecting the skin and mucous membranes of humans and, depending on its subtype and the persistence of the infection, is associated with the appearance of anogenital and cutaneous warts and neoplasms of the anogenital tract, the most frequent being cervical cancer11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039 [https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039)-22. Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Estimativa 2020: incid\u00eancia de c\u00e2ncer no Brasil [Internet]. Rio Janeiro: INCA; 2019 [cited 2019 Mar 22]. Available from: Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf [https://www.inca.gov.br/sites/ufu.sti.in...\n](https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf).\nCervical cancer is a preventable, curable disease with high morbidity and mortality worldwide. In Brazil, this type of cancer ranks third among malignant neoplasms in women and fourth in mortality22. Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Estimativa 2020: incid\u00eancia de c\u00e2ncer no Brasil [Internet]. Rio Janeiro: INCA; 2019 [cited 2019 Mar 22]. Available from: Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf\n[https://www.inca.gov.br/sites/ufu.sti.in...\n](https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf). The main strategy to control this neoplasm is primary prevention using the HPV vaccine11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039 [https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039).\nThe HPV vaccine was introduced worldwide more than ten years ago, but many countries still find barriers to maintain vaccination coverage rates at recommended levels11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039\n[https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039),33. World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind [https://www.who.int/publications/m/item/...\n](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind). In Brazil, the goal estimated by the Ministry of Health (MS), for each dose, is 80%44. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf [https://sbim.org.br/images/files/notas-t...\n](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf)-55. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D [http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D). Previous studies prove that the goal recommended by the MS covers a large part of the target population, adolescents, since this vaccine should preferably be administered before the beginning of sexual life due to the natural history of the disease. Moreover, this goal aims to achieve collective protection against HPV, thus avoiding cervical cancer11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039 [https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039),33. World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind [https://www.who.int/publications/m/item/...\n](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind)\n4. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf\n[https://sbim.org.br/images/files/notas-t...\n](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf)\n5. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D\n[http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D)-66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528).\nIn 2020, the World Health Organization (WHO) launched a global strategy for the elimination of cancer, establishing the increase of goals by the year 203033. World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind\n[https://www.who.int/publications/m/item/...\n](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind). One of these goals is for countries to reach a 90% HPV vaccination rate for all target audiences, i.e., girls and boys aged 9 to 15 years33. World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind [https://www.who.int/publications/m/item/...\n](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind).\nIn Brazil, the implementation of the HPV vaccine in the calendar of the National Immunization Program (PNI) occurred in 2014 and, since then, a vaccination routine has been gradually established44. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf\n[https://sbim.org.br/images/files/notas-t...\n](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf)-55. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D [http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D). Currently, this vaccine is offered to both female and male adolescents, in the age groups 9 to 13 years and 11 to 14 years, respectively, in a two-dose regiment, with a six-month interval in between44. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf [https://sbim.org.br/images/files/notas-t...\n](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf). To achieve fully effective immunity, the vaccine must be applied in its complete regimen, that is, in two doses, according to the age group and the established criteria44. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf [https://sbim.org.br/images/files/notas-t...\n](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf)-55. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D [http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D).\nRegarding HPV vaccine coverage rates in Brazil, they are not considerably different from vaccine coverage in other countries but are insufficient to achieve the global goal for the eradication of cervical cancer33. World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind\n[https://www.who.int/publications/m/item/...\n](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind),66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528)-77. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291 [https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291). In 2014, soon after its implementation, 87% of Brazilian municipalities reached the goal recommended with the first dose, but only 32% of them reached the goal recommended with the second dose66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528). Currently, the coverage rates of the second dose are increasingly lower throughout the Brazilian territory.\nThe analyses on the vaccination strategy of the first and second dose of this vaccine show that the first was performed on a large scale and with great coverage by the media, being widely disseminated and offered in municipal and state schools66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528\n[https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528)\n7. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291\n[https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291)-88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z). This aspect may justify the above average rates recommended in almost the entire national territory. Regarding the second dose and subsequent years, however, the HPV vaccine started to be offered only in health centers, which may be one of the reasons for the low rates of vaccination coverage66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528)\n7. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291\n[https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291)-88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z).\nThe search for increased vaccination rates for adolescents creates many challenges. Among which, we highlight the decision to vaccinate, either made by those responsible for the adolescents or by the adolescents\u2019 themselves. Regarding the rejection of this vaccine, it occurs mostly due to the spread of fake news88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z\n[https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z).\nOverall, the acceptability of vaccines is a complex process that can be affected by several factors. Regarding the decision to vaccinate, in 2014, the Strategic Advisory Group of Experts (SAGE) sought to understand the determinant factors of vaccination99. Appendices to the report of the Sage Working Group on Vaccine Hesitancy [Internet]. 2014 [cited 2014 Apr 22]. Available from: Available from: https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy\n[https://www.comminit.com/polio/content/a...\n](https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy).\nThe group developed a model organized in three main areas: (1) contextual influences: historical, sociocultural, environmental, health system/institutional, economic or political factors; (2) individual and group influences: arising from the personal perception of the vaccine or influences of the social environment; and (3) specific vaccines issues: which are those directly related to the characteristics of the vaccine or the process of vaccination99. Appendices to the report of the Sage Working Group on Vaccine Hesitancy [Internet]. 2014 [cited 2014 Apr 22]. Available from: Available from: https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy\n[https://www.comminit.com/polio/content/a...\n](https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy). The term \u201cvaccination hesitation\u201d was defined as the delay in accepting or the rejection to the vaccine, despite its availability99. Appendices to the report of the Sage Working Group on Vaccine Hesitancy [Internet]. 2014 [cited 2014 Apr 22]. Available from: Available from: https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy [https://www.comminit.com/polio/content/a...\n](https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy).\nOther contributing factors are added to the adolescents\u2019 low access to vaccines, such as: social and economic vulnerability and issues related to the difficulties for this public to access health services, often because they do not seek care and, when they seek it, they find little guidance (few of which are correct) from health professionals11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039\n[https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039),88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z),1010. Fern\u00e1ndez-Feito A, Lana A, Par\u00e1s Bravo P, Pellico L\u00f3pez A, Paz-Zulueta M. Knowledge of the Human Papillomavirus by Social Stratification Factors. Nurs Res. 2020;69(3):E18-E25. https://doi.org/10.1097/NNR.0000000000000413 [https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)\n11. Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017;4:22-5. https://doi.org/10.1097/NNR.0000000000000413\n[https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)-1212. Moura LL, Code\u00e7o CT, Luz PM. Cobertura da vacina papilomav\u00edrus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes et\u00e1rias. Rev Bras Epidemiol. 2021;24. https://doi.org/10.1590/1980-549720210001 [https://doi.org/10.1590/1980-54972021000...\n](https://doi.org/10.1590/1980-549720210001). Thus, we can observe the significant role the nursing professional plays in this scenario. In Brazil, this professional is mostly responsible for the management of primary health care services and is at the forefront of vaccination campaigns, playing an extremely politically relevant role in gaining a better adhesion of adolescents, besides being a reference for the health team77. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291 [https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291)-88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z),1010. Fern\u00e1ndez-Feito A, Lana A, Par\u00e1s Bravo P, Pellico L\u00f3pez A, Paz-Zulueta M. Knowledge of the Human Papillomavirus by Social Stratification Factors. Nurs Res. 2020;69(3):E18-E25. https://doi.org/10.1097/NNR.0000000000000413 [https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)\n11. Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017;4:22-5. https://doi.org/10.1097/NNR.0000000000000413\n[https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)-1212. Moura LL, Code\u00e7o CT, Luz PM. Cobertura da vacina papilomav\u00edrus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes et\u00e1rias. Rev Bras Epidemiol. 2021;24. https://doi.org/10.1590/1980-549720210001 [https://doi.org/10.1590/1980-54972021000...\n](https://doi.org/10.1590/1980-549720210001).\nGiven this context and a lack of Brazilian literature on vaccination and environment specific to the adolescent public, we seek to understand the factors related to the low vaccination rate of HPV vaccination among adolescents, especially from the perspective of the social environment. From the point of view of individual factors, the scientific literature shows that low educational level, low income, difficulty in accessing health services, place of residence, dogmas brought by the media and religious beliefs, in addition to low knowledge and information about the epidemiology of HPV cancer and its vaccine, are predictors for low vaccination rate within this public66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528\n[https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528)-77. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291 [https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291),99. Appendices to the report of the Sage Working Group on Vaccine Hesitancy [Internet]. 2014 [cited 2014 Apr 22]. Available from: Available from: https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy [https://www.comminit.com/polio/content/a...\n](https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy)\n10. Fern\u00e1ndez-Feito A, Lana A, Par\u00e1s Bravo P, Pellico L\u00f3pez A, Paz-Zulueta M. Knowledge of the Human Papillomavirus by Social Stratification Factors. Nurs Res. 2020;69(3):E18-E25. https://doi.org/10.1097/NNR.0000000000000413\n[https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)\n11. Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017;4:22-5. https://doi.org/10.1097/NNR.0000000000000413\n[https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)\n12. Moura LL, Code\u00e7o CT, Luz PM. Cobertura da vacina papilomav\u00edrus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes et\u00e1rias. Rev Bras Epidemiol. 2021;24. https://doi.org/10.1590/1980-549720210001\n[https://doi.org/10.1590/1980-54972021000...\n](https://doi.org/10.1590/1980-549720210001)-1313. Thompson EL, Rosen BL, Maness SB. Social Determinants of Health and Human Papillomavirus Vaccination Among Young Adults, National Health Interview Survey 2016. J Community Health. 2019;44:149-58. https://doi.org/10.1007/s10900-018-0565-2 [https://doi.org/10.1007/s10900-018-0565-...\n](https://doi.org/10.1007/s10900-018-0565-2).\nThus, this study aims to analyze the association between the factors of the social environment and the coverage rates of the human papillomavirus vaccine in adolescents from the State of Minas Gerais (MG), Brazil.\nMethod\nStudy design\nThis is an epidemiological, ecological study, in which panel and trend analysis were carried out.\nLocation\nThe study was conducted in the state of Minas Gerais, Brazil.\nPeriod\nThe study was conducted from 2016 to 2020.\nStudy population\nThe study population consisted of female and male adolescents, aged 9 to 13 years, who were vaccinated against HPV.\nThe period and age group framing of this study is justified since it focuses the target audience of the vaccine in question and encompasses the completeness/consolidation of the online system data from 2016.\nThe state of Minas Gerais consists of 853 municipalities, divided into 19 Regional Health Superintendence (Superintend\u00eancias Regionais de Sa\u00fade - SRS) and 9 Regional Health Management Units (Ger\u00eancias Regionais de Sa\u00fade - GRS). The municipalities are delimited from cultural, economic, and social identities and shared transport networks and networks, with the purpose of integrating the organization and planning of health actions and services1414. Santos L. Regi\u00e3o de sa\u00fade e suas redes de aten\u00e7\u00e3o: modelo organizativo-sist\u00eamico do SUS. Cien Saude Colet. 2017;22(4):1281-9. https://doi.org/10.1590/1413-81232017224.26392016\n[https://doi.org/10.1590/1413-81232017224...\n](https://doi.org/10.1590/1413-81232017224.26392016).\nThey are Alfenas, Barbacena, Belo Horizonte, Coronel Fabriciano, Diamantina, Divin\u00f3polis, Governador Valadares, Itabira, Ituiutaba, Janu\u00e1ria, Juiz de Fora, Leopoldina, Manhua\u00e7u, Montes Claros, Passos, Patos de Minas, Pedra Azul, Pirapora, Ponte Nova, Pouso Alegre, S\u00e3o Jo\u00e3o Del Rei, Sete Lagoas, Te\u00f3filo Otoni, Ub\u00e1, Uberaba, Uberl\u00e2ndia, Una\u00ed, and Varginha.\nStudy variables\nAll data from this study were extracted through secondary databases, available on government websites.\nThe HPV vaccine data were extracted from the Information System of the National Immunization Program (SI-PNI), available in the public domain (\n[http://sipni.datasus.gov.br/si-pni-web/faces/inicio.jsf](http://sipni.datasus.gov.br/si-pni-web/faces/inicio.jsf)).\nDemographic data were extracted from the platform of the Atlas of Human Development in Brazil (\n[http://atlasbrasil.org.br/consulta/planilha](http://atlasbrasil.org.br/consulta/planilha)), and data on social characteristics were obtained by the State Department of Justice and Public Security (Secretaria de Estado de Justi\u00e7a e Seguran\u00e7a P\u00fablica - SEJUSP) ( [http://www.seguranca.mg.gov.br/2018-08-22-13-39-06/dados-abertos](http://www.seguranca.mg.gov.br/2018-08-22-13-39-06/dados-abertos)).\nIn this study, the variable of interest (dependent) was the coverage rate of the second dose (D2) of the HPV vaccine, due to studies related to its immunogenicity, efficacy, and effectiveness44. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf\n[https://sbim.org.br/images/files/notas-t...\n](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf)-55. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D [http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D). Thus, individuals must have taken the first dose (D1) and, subsequently, D2.\nThe independent variables were selected through a literature review. Those that demonstrated a possible association with the variable of interest were considered11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039\n[https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039),66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528)\n7. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291\n[https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291)-88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z),1010. Fern\u00e1ndez-Feito A, Lana A, Par\u00e1s Bravo P, Pellico L\u00f3pez A, Paz-Zulueta M. Knowledge of the Human Papillomavirus by Social Stratification Factors. Nurs Res. 2020;69(3):E18-E25. https://doi.org/10.1097/NNR.0000000000000413 [https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)\n11. Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017;4:22-5. https://doi.org/10.1097/NNR.0000000000000413\n[https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413)\n12. Moura LL, Code\u00e7o CT, Luz PM. Cobertura da vacina papilomav\u00edrus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes et\u00e1rias. Rev Bras Epidemiol. 2021;24. https://doi.org/10.1590/1980-549720210001\n[https://doi.org/10.1590/1980-54972021000...\n](https://doi.org/10.1590/1980-549720210001)-1313. Thompson EL, Rosen BL, Maness SB. Social Determinants of Health and Human Papillomavirus Vaccination Among Young Adults, National Health Interview Survey 2016. J Community Health. 2019;44:149-58. https://doi.org/10.1007/s10900-018-0565-2 [https://doi.org/10.1007/s10900-018-0565-...\n](https://doi.org/10.1007/s10900-018-0565-2). Among which, the following were mentioned: the coverage rates of HPV vaccine D1; municipal human development index (MHDI); municipal human development index income (MHDI income); municipal human development index education (MHDI education); municipal human development index longevity (MHDI longevity), and violence rate per 100,000 for each SRS/GRS.\nThe rate of violence comprises consolidated data on violent crimes: sum of the records of consummated rape; consummated rape of vulnerable; attempted rape of vulnerable; attempted rape; consummated extortion; attempted extortion; extortion by consummate kidnapping; attempted homicide; consummated theft; attempted theft; consummate kidnapping and false imprisonment; attempted kidnapping and false imprisonment; and consummated homicide. For the consistency of the study, pre-analysis tests were performed to reach these selected variables.\nData processing and analysis\nFor data analysis, the Stata software, version 16.0, was used. The vaccination goals for D2 of the HPV vaccine were estimates by year and by SRS and GRS.\nFor trend analysis, the Prais-Winsten autoregressive model was employed, using the vaccination rate (by year and by SRS and GRS) as dependent variables and the year of the study as independent variable (2016-2020).\nFor this, the rate of vaccine coverage per year, per SRS and GRS had to be transformed to a logarithmic scale to reduce the heterogeneity of variance of the residues from the time series regression analysis.\nAfter the analytical procedure of trend analysis, the annual percent change (APC) was performed for the dependent variable analyzed. The following formula was used: APC=(-1+10 [b1]*100%), in which b1 refers to the angular coefficient of Prais-Winsten regression. For the entire analytical procedure, the significance level of 5% was adopted. For the calculation of the 95% confidence interval (95%CI) of the PCA measurements, the following formulas were used: 95%CI minimum=(-1+10 [b1-t*e]*100%); and 95% CI maximum=(-1+10 [b1+t*e ]*100%), in which the values of coefficient b1 (standard error) were generated by the statistical analysis program; the t refers to the 95% percentile of the T-student distribution test and corresponds to 4 degrees of freedom (2.776), which refers to the five years of analysis.\nPanel analysis was also performed, since this type of analysis makes it possible to identify structural changes in the relationship between the dependent and independent variable, considering that it accompanies a given sample of individuals (regions) in time. In total, 28 SRS/GRS from the state of Minas Gerais were evaluated, all of which presented complete data in all variables, thus constituting a balanced panel analysis by SRS/GRS and by year of analysis. The random effect model was adopted, since regional variations are identified by random oscillations around a constant mean value, thus being more efficient and with less variability. Panel regression is demonstrated by the formula below:\nIn the formula, Y represents the dependent variable, \u03b2 represents the variation observed in Y when the independent variable, X, increases in one unit and \u03b5 indicates the stochastic nature of the model. Subscript i indicates that observations are indexed by case. Subscripts i and t report that the observations are indexed, respectively, by GRS and time. The model becomes more powerful since information is accumulated on the relationship between sociodemographic and socio-environmental conditions for all GRS and years.\nFinally, the Hausman test was performed to verify the consistency of the model.\nEthical aspects\nSince this study used free access data, the project was not required to be submitted to the Research Ethics Committee, according to resolution 466/2012 of the National Health Council1717. Novoa PCR. What changes in Research Ethics in Brazil: Resolution no. 466/12 of the National Health Council. Einstein (S\u00e3o Paulo). 2014;12(1). https://doi.org/10.1590/S1679-45082014ED3077\n[https://doi.org/10.1590/S1679-45082014ED...\n](https://doi.org/10.1590/S1679-45082014ED3077).\nResults\nThis analysis resulted in 140 annual observations regarding HPV vaccination rates in the period from 2016 to 2020, related to the 19 SRS and 8 GRS in the State of Minas Gerais, Brazil.\n[Table 1]() shows HPV vaccine coverage rates by age group, year, and trend. We observed that the variations in coverage rates had a higher proportion in the 9-year-old age group, and in 2017 the highest rate occurred for D1. On the other hand, the lowest rate occurred for the older ages, with the 13-year-old age group being the one that stood out the most from the other groups. Regarding trend analyses, we found that only the 9-year-old age group was increasing, and all other age groups were decreasing.\nAnalysis of HPV vaccine coverage in the State of Minas Gerais. Belo Horizonte, State of Minas Gerais, Brazil, 2016-2020\n[Table 2]() shows the coverage rate of the HPV vaccine related to D2 by SRS/GRS per year. We observed that all regions presented rates lower than expected for D2 coverage; these rates show a stationary trend over the years. SRS Alfenas exhibited the highest D2 rate in 2017 (42,16) and the SRS of Patos de Minas had the lowest rate, in 2016 (11,2).\nD2 coverage rate of HPV vaccine in the 9-year-old age group, by SRS/GRS, in the State of Minas Gerais. Belo Horizonte, MG, Brazil, 2016-2020\nThe regions of Ponte Nova and Ub\u00e1 have shown an increasing trend over the years. In Passos, the opposite (descending) occurred.\n[Table 3]() presents the data regarding the environment over the years. For the variables related to the human development index (HDI), data were presented only for the year 2016, since this variable did not change over the years, since its estimate was carried out by the 2010 demographic census.\nEnvironmental data of the State of Minas Gerais. Belo Horizonte, State of Minas Gerais, Brazil, 2016-2020\nFinally, the panel analysis (\n[Table 4]()) shows the final model of the study, balanced by SRS/SRG and by year of analysis, for the group of 9-year-olds, due to its power of significance.\nFinal model for the group of 9-year-old in the State of Minas Gerais. Belo Horizonte, State of Minas Gerais, Brazil, 2016-2020\nThe independent variables coverage rate of D1, HDI longevity and rate of violence significantly interfered in the coverage rates of D2, presenting with a p-value<0.005; this model was explained with a power of 93.2% of statistical significance.\nRegarding the consistency of the model, the p-value was 0.0025 by the Hausman test, which justifies the use of the fixed effects model being more significant for this study.\nDiscussion\nThe results of this study showed that HPV vaccine coverage rates in the state of Minas Gerais are well below the expected targets for all the SRS/SRG and age groups, and most regions showed a stationary and decreasing trend. Regarding the contextual factors associated with the coverage rate of the HPV vaccine, we observed that the variables of D1 coverage rate, MHDI longevity, and rate of violence influenced the D2 coverage rates.\nAmong the years of the study, 2017 had a small difference in the coverage rates of D2 compared to the previous year, this result is justified by the fact that 2017 was the year in which the HPV vaccine was introduced for the male adolescent population in Brazil. However, these rates did not reach the expected increasing values, nor the ones obtained in other countries1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737\n[https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737).\nAustralia, a pioneer country in the introduction of HPV vaccine in its national vaccination program for both girls and boys, currently has good results in reducing the incidence of cervical cancer thanks to the vaccination coverage rate, which ranges from 70% to 80% throughout its territory1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737\n[https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737)-1919. Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters. 2008;16(32):97-103. https://doi.org/10.1016/S0968-8080(08)32413-6 [https://doi.org/10.1016/S0968-8080(08)32...\n](https://doi.org/10.1016/S0968-8080(08)32413-6).\nBrazil was the first country in South America and the seventh in the world to offer the HPV vaccine to boys in national immunization programs. The availability of immunobiological strains for boys also provides cross-protection for girls, in addition to protecting against cancers in the penis, throat, and anus, all diseases that are directly related to HPV11. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039\n[https://doi.org/10.1016/j.canlet.2019.11...\n](https://doi.org/10.1016/j.canlet.2019.11.039),55. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D [http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D),1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737 [https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737). However, for this to happen, the coverage rates for this public must be within the established goals55. Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D [http://www.riocomsaude.rj.gov.br/Publico...\n](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D)-66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528),1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737 [https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737).\nAnother finding of this study refers to the fact that the year 2020 presented the lowest coverage rates (0.83 for D1, and 1.83 for D2). This fact is very relevant and worrisome, since it probably relates to the year of the beginning of the coronavirus pandemic (COVID-19).\nStudies show that the COVID-19 pandemic had a significant influence on public health and that HPV vaccine coverage was also affected2020. Silva TMR, S\u00e1 ACMGN, Beinner MA, Abreu MNS, Matozinhos FP, Sato APS, et al. Impact of the COVID-19 Pandemic on Human Papillomavirus Vaccination in Brazil. Int J Public Health. 2022;(39). https://doi.org/10.3389/ijph.2022.1604224\n[https://doi.org/10.3389/ijph.2022.160422...\n](https://doi.org/10.3389/ijph.2022.1604224). However, this reality is not exclusive to this vaccine, but it is one shared with other regular vaccines2020. Silva TMR, S\u00e1 ACMGN, Beinner MA, Abreu MNS, Matozinhos FP, Sato APS, et al. Impact of the COVID-19 Pandemic on Human Papillomavirus Vaccination in Brazil. Int J Public Health. 2022;(39). https://doi.org/10.3389/ijph.2022.1604224 [https://doi.org/10.3389/ijph.2022.160422...\n](https://doi.org/10.3389/ijph.2022.1604224)\n21. Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400-7. https://doi.org/10.1080/21645515.2020.1804776\n[https://doi.org/10.1080/21645515.2020.18...\n](https://doi.org/10.1080/21645515.2020.1804776)\n22. Bruni L, Saura-L\u00e1zaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med (Baltimore). 2021 Mar 1;144:106399. https://doi.org/10.1016/j.ypmed.2020.106399\n[https://doi.org/10.1016/j.ypmed.2020.106...\n](https://doi.org/10.1016/j.ypmed.2020.106399)-2323. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821. https://doi.org/10.2471/BLT.11.089862 [https://doi.org/10.2471/BLT.11.089862...\n](https://doi.org/10.2471/BLT.11.089862).\nIn the comparison between the cohorts, the coverage achieved with the first and second dose indicated that the younger cohorts were more likely to be vaccinated, both by SRS/SRG and per year, presenting an increasing trend. This is an extremely relevant factor within the context of HPV vaccination; the population in this age group is the one that benefits most from this immunobiological, since people have not yet been exposed to the viral subtypes of HPV - which makes the vaccine have a greater power of efficacy and immunogenicity against the subtypes of the applied vaccine88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z\n[https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z),1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737 [https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737),2323. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821. https://doi.org/10.2471/BLT.11.089862 [https://doi.org/10.2471/BLT.11.089862...\n](https://doi.org/10.2471/BLT.11.089862).\nThis targeted age group of the HPV vaccine is an important and relevant factor for public health, since historically most immunization programs have focused on childhood vaccination. Thu, health services may be less experienced in reaching and vaccinating adolescents33. World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind\n[https://www.who.int/publications/m/item/...\n](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind),77. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291 [https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291)-88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z). This fact can be proven by the low rates of vaccination coverage found in this study, as well as in other countries, since many have limited experience in providing and continuing health care to adolescents, in addition to beliefs/barriers imposed in the context of this immunobiological66. Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528 [https://doi.org/10.24302/sma.v6i2.1528...\n](https://doi.org/10.24302/sma.v6i2.1528)\n7. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291\n[https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291)-88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z [https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z),1010. Fern\u00e1ndez-Feito A, Lana A, Par\u00e1s Bravo P, Pellico L\u00f3pez A, Paz-Zulueta M. Knowledge of the Human Papillomavirus by Social Stratification Factors. Nurs Res. 2020;69(3):E18-E25. https://doi.org/10.1097/NNR.0000000000000413 [https://doi.org/10.1097/NNR.000000000000...\n](https://doi.org/10.1097/NNR.0000000000000413).\nIn this study, we also found similarity in vaccination coverage rates among the regions of Minas Gerais (SRS/GRS), which may be associated with regional and even state-level public policies.\nTo improve HPV vaccine coverage rates, low- and middle-income countries, such as India, Peru, Uganda, and Vietnam, have adopted vaccination strategies within community and schools. They emphasize that, to increase the acceptability of this vaccine, other interventions are needed, such as sex education, knowledge, and good health practices. Many of these actions are performed by the nursing professionals88. Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z\n[https://doi.org/10.1186/s12889-016-2845-...\n](https://doi.org/10.1186/s12889-016-2845-z),1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737 [https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737)-1919. Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters. 2008;16(32):97-103. https://doi.org/10.1016/S0968-8080(08)32413-6 [https://doi.org/10.1016/S0968-8080(08)32...\n](https://doi.org/10.1016/S0968-8080(08)32413-6),2222. Bruni L, Saura-L\u00e1zaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med (Baltimore). 2021 Mar 1;144:106399. https://doi.org/10.1016/j.ypmed.2020.106399 [https://doi.org/10.1016/j.ypmed.2020.106...\n](https://doi.org/10.1016/j.ypmed.2020.106399)-2323. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821. https://doi.org/10.2471/BLT.11.089862 [https://doi.org/10.2471/BLT.11.089862...\n](https://doi.org/10.2471/BLT.11.089862).\nRegarding the characteristics of the social environment, the analysis presented here suggests an association between low vaccination coverage and high crime rates by region. Studies show that regions with higher value of this indicator can represent both more rural areas and urban areas of low economic level, which causes strong consequences for economic, social, and health development2323. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821. https://doi.org/10.2471/BLT.11.089862\n[https://doi.org/10.2471/BLT.11.089862...\n](https://doi.org/10.2471/BLT.11.089862)\n24. Pinto AFR, Rocha LEV. Evolu\u00e7\u00e3o e Din\u00e2mica Territorial da Criminalidade Violenta no Estado de Minas Gerais [Internet]. 2022 [cited 2022 Apr 22]. Available from: Available from: https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf\n[https://brsa.org.br/wp-content/uploads/w...\n](https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf)-2525. Dub\u00e9 E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy-country-specific characteristics of a global phenomenon. Vaccine. 2014;32(49):6649-54. https://doi.org/10.1016/j.vaccine.2014.09.039 [https://doi.org/10.1016/j.vaccine.2014.0...\n](https://doi.org/10.1016/j.vaccine.2014.09.039).\nGeographical barriers can also influence the reduction of access to vaccination services2424. Pinto AFR, Rocha LEV. Evolu\u00e7\u00e3o e Din\u00e2mica Territorial da Criminalidade Violenta no Estado de Minas Gerais [Internet]. 2022 [cited 2022 Apr 22]. Available from: Available from: https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf\n[https://brsa.org.br/wp-content/uploads/w...\n](https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf). The SAGE group related, for example, geographical barriers to the hesitation to vaccinate. This occurred when the population was motivated to receive a vaccine but hesitated due to the fact that the health center was distant, or its access was hindered99. Appendices to the report of the Sage Working Group on Vaccine Hesitancy [Internet]. 2014 [cited 2014 Apr 22]. Available from: Available from: https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy [https://www.comminit.com/polio/content/a...\n](https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy) - this difficulty may be imposed by the insecurity of going to the health service2424. Pinto AFR, Rocha LEV. Evolu\u00e7\u00e3o e Din\u00e2mica Territorial da Criminalidade Violenta no Estado de Minas Gerais [Internet]. 2022 [cited 2022 Apr 22]. Available from: Available from: https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf [https://brsa.org.br/wp-content/uploads/w...\n](https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf) due to the rates of violence in each region.\nThus, crime can directly interfere in the performance of health care by limiting access to services, causing the population not to attend the health unit2525. Dub\u00e9 E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy-country-specific characteristics of a global phenomenon. Vaccine. 2014;32(49):6649-54. https://doi.org/10.1016/j.vaccine.2014.09.039\n[https://doi.org/10.1016/j.vaccine.2014.0...\n](https://doi.org/10.1016/j.vaccine.2014.09.039)\n26. Silva LOL, Dias CA, Soares MM, Rodrigues SM. Acessibilidade ao servi\u00e7o de sa\u00fade: percep\u00e7\u00f5es de usu\u00e1rios e profissionais de sa\u00fade. Cogitare Enferm. 2011;16(4). https://doi.org/10.5380/ce.v16i4.25434\n[https://doi.org/10.5380/ce.v16i4.25434...\n](https://doi.org/10.5380/ce.v16i4.25434)-2727. Elizondo-Alzola U, Carrasco MG, Pin\u00f3s L, Picchio CA, Riuss C, Diez E. Vaccine hesitancy among paediatric nurses: Prevalence and associated factors. PloS One. 2021;16(5):e0251735. https://doi.org/10.1371/journal.pone.0251735 [https://doi.org/10.1371/journal.pone.025...\n](https://doi.org/10.1371/journal.pone.0251735). Again, we emphasize that, to our knowledge, there are few national studies that address the impact of crime index, especially on the health of adolescents.\nTerritorial characteristics, such as regional inequalities and the peculiar characteristics of each state/region (public security policies, economic infrastructure, health, education, and demographic structure), are extremely important factors for the development of public health strategies1818. Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737\n[https://doi.org10.2807/1560-7917.ES.2018...\n](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737)-1919. Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters. 2008;16(32):97-103. https://doi.org/10.1016/S0968-8080(08)32413-6 [https://doi.org/10.1016/S0968-8080(08)32...\n](https://doi.org/10.1016/S0968-8080(08)32413-6),2323. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821. https://doi.org/10.2471/BLT.11.089862 [https://doi.org/10.2471/BLT.11.089862...\n](https://doi.org/10.2471/BLT.11.089862). When developing strategies to raise awareness of the importance of HPV vaccination, it is necessary to adapt them according to the socioeconomic and socio-environmental characteristics of the location. In this case, the nursing professional is able to contribute to this process through situational analysis of the population and with the use of tools, such as situational diagnosis77. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291 [https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291),2727. Elizondo-Alzola U, Carrasco MG, Pin\u00f3s L, Picchio CA, Riuss C, Diez E. Vaccine hesitancy among paediatric nurses: Prevalence and associated factors. PloS One. 2021;16(5):e0251735. https://doi.org/10.1371/journal.pone.0251735 [https://doi.org/10.1371/journal.pone.025...\n](https://doi.org/10.1371/journal.pone.0251735).\nMoreover, nurses within health centers develop actions to prevent diseases and promote health, which includes one of the measures of early diagnosis of cervical cancer - the performance of the Pap smear test. Thus, nurses are able, for example, to analyze the rates of altered tests, as well as the coverage rates of the HPV vaccine, and to develop strategies that encourage adolescents to seek vaccination. The strategies adopted for the adolescent public and the HPV vaccine are very recent in our country, mainly due to the taboo surrounding this vaccine77. Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291\n[https://doi.org/10.37689/acta-ape/2022AO...\n](https://doi.org/10.37689/acta-ape/2022AO02291),2727. Elizondo-Alzola U, Carrasco MG, Pin\u00f3s L, Picchio CA, Riuss C, Diez E. Vaccine hesitancy among paediatric nurses: Prevalence and associated factors. PloS One. 2021;16(5):e0251735. https://doi.org/10.1371/journal.pone.0251735 [https://doi.org/10.1371/journal.pone.025...\n](https://doi.org/10.1371/journal.pone.0251735).\nFinally, this study presents some limitations: the research was developed based on data from secondary databases, which presented limited information (such as the data not being segregated by gender), in addition to the model being adjusted only for the 9-year-old age group, due to the fact that the other age groups have very low vaccination coverage rates.\nDespite the potential limitations, we emphasize that the goal of HPV vaccine coverage by the year 2030 is aligned with the coverage targets of 90% to 95% established for other childhood vaccines, such as diphtheria-tetanus-pertussis (DTaP) and measles vaccines2121. Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400-7. https://doi.org/10.1080/21645515.2020.1804776\n[https://doi.org/10.1080/21645515.2020.18...\n](https://doi.org/10.1080/21645515.2020.1804776). Despite all the challenges, including those related to the social environment (such as crime rates), for the state of MG to become a reference in relation to the vaccination of adolescents and to reach the recommended targets for the HPV vaccine, it is necessary to intensify of public policies aimed at health education, as well as the awareness of the target audience of the vaccine and of managers and health professionals - especially nurses - about this very important issue. The professional nurse undoubtedly has a fundamental role in the implementation of such actions and vaccination strategies for adolescents, considering all their care specificities. They play a fundamental role in the implementation of such vaccination actions and strategies for adolescents, considering all their specificities of care.\nConclusion\nThe evidence found in this study may contribute to improve the understanding of the complex relationship between environmental and individual determinants and vaccination, which may play an important role in expanding public health strategies and policies. We aim to contribute to the increase in vaccination coverage rates in adolescent public not only within the State of Minas Gerais but also within the entire country.\nThe analysis of panel data, social environment, and vaccination is recent in the field of public health, but it is extremely important. This study confirms that, although tenuous, aspects of the environment, in addition to individual characteristics, provide relevant information for the understanding of the occurrence of health outcomes: the impact of HPV vaccine rates in terms of public health will occur if 90% of vaccination coverage is reached among adolescents. The effective operationalization toward this goal is extremely relevant and necessary for the eradication of cervical cancer and other HPV-associated diseases/neoplasms.\nAcknowledgments\nWe thank the research group at the N\u00facleo de Estudo e Pesquisa em Vacina\u00e7\u00e3o (NUPESV) for the encouragement during this study.\nReferences\n-\n1Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 Feb 28;471:88-102. https://doi.org/10.1016/j.canlet.2019.11.039\n[\u00bb https://doi.org/10.1016/j.canlet.2019.11.039](https://doi.org/10.1016/j.canlet.2019.11.039)\n-\n2Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Estimativa 2020: incid\u00eancia de c\u00e2ncer no Brasil [Internet]. Rio Janeiro: INCA; 2019 [cited 2019 Mar 22]. Available from: Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf\n[\u00bb https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf](https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf)\n-\n3World Health Organization. Developing together the vision and strategy for immunization - 2021-2030. Immunization Agenda 2030: a global strategy to leave no one behind [Internet]. Geneva: WHO; 2019 [cited 2019 Feb 22]. Available from: Available from: https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind\n[\u00bb https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind](https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind)\n-\n4Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Of\u00edcio 203/2021/CGPNI/DEIDT/SVS/MS [Internet]. 2021 [cited 2021 Mar 22]. Available from: Available from: https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf\n[\u00bb https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf](https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf)\n-\n5Minist\u00e9rio da Sa\u00fade (BR), Secret\u00e1ria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia de Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o Geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico sobre a vacina papilomav\u00edrus humano (HPV) na aten\u00e7\u00e3o b\u00e1sica [Internet]. Bras\u00edlia: MS; 2013 [cited 2014 Abr 22]. Available from: Available from: http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D\n[\u00bb http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D)\n-\n6Moro A, Santos CL, Couto MP, \u00c1vila LB, Ditterich RG, Mazon LM. Coberturas vacinais do papiloma v\u00edrus humano no contexto brasileiro. Sa\u00fade Meio Ambiente Rev Interdisciplinar. 2017;6(2):124-32. https://doi.org/10.24302/sma.v6i2.1528\n[\u00bb https://doi.org/10.24302/sma.v6i2.1528](https://doi.org/10.24302/sma.v6i2.1528)\n-\n7Panobianco MS, Bezerril AV, Nunes LC, Mairink APAR, Gozzo TO, Canete ACS, et al. Conhecimento de acad\u00eamicos de enfermagem sobre a vacina contra o papilomav\u00edrus humano. Acta Paul Enferm. 2022;35:eAPE02291. https://doi.org/10.37689/acta-ape/2022AO02291\n[\u00bb https://doi.org/10.37689/acta-ape/2022AO02291](https://doi.org/10.37689/acta-ape/2022AO02291)\n-\n8Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: A systematic review. BMC Public Health. 2016 Feb 19;16:172. https://doi.org/10.1186/s12889-016-2845-z\n[\u00bb https://doi.org/10.1186/s12889-016-2845-z](https://doi.org/10.1186/s12889-016-2845-z)\n-\n9Appendices to the report of the Sage Working Group on Vaccine Hesitancy [Internet]. 2014 [cited 2014 Apr 22]. Available from: Available from: https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy\n[\u00bb https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy](https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy)\n-\n10Fern\u00e1ndez-Feito A, Lana A, Par\u00e1s Bravo P, Pellico L\u00f3pez A, Paz-Zulueta M. Knowledge of the Human Papillomavirus by Social Stratification Factors. Nurs Res. 2020;69(3):E18-E25. https://doi.org/10.1097/NNR.0000000000000413\n[\u00bb https://doi.org/10.1097/NNR.0000000000000413](https://doi.org/10.1097/NNR.0000000000000413)\n-\n11Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et al. What works for human papillomavirus vaccine introduction in low and middle-income countries? Papillomavirus Res. 2017;4:22-5. https://doi.org/10.1097/NNR.0000000000000413\n[\u00bb https://doi.org/10.1097/NNR.0000000000000413](https://doi.org/10.1097/NNR.0000000000000413)\n-\n12Moura LL, Code\u00e7o CT, Luz PM. Cobertura da vacina papilomav\u00edrus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes et\u00e1rias. Rev Bras Epidemiol. 2021;24. https://doi.org/10.1590/1980-549720210001\n[\u00bb https://doi.org/10.1590/1980-549720210001](https://doi.org/10.1590/1980-549720210001)\n-\n13Thompson EL, Rosen BL, Maness SB. Social Determinants of Health and Human Papillomavirus Vaccination Among Young Adults, National Health Interview Survey 2016. J Community Health. 2019;44:149-58. https://doi.org/10.1007/s10900-018-0565-2\n[\u00bb https://doi.org/10.1007/s10900-018-0565-2](https://doi.org/10.1007/s10900-018-0565-2)\n-\n14Santos L. Regi\u00e3o de sa\u00fade e suas redes de aten\u00e7\u00e3o: modelo organizativo-sist\u00eamico do SUS. Cien Saude Colet. 2017;22(4):1281-9. https://doi.org/10.1590/1413-81232017224.26392016\n[\u00bb https://doi.org/10.1590/1413-81232017224.26392016](https://doi.org/10.1590/1413-81232017224.26392016)\n-\n15Antunes JLF, Cardoso MRA. Uso da an\u00e1lise de s\u00e9ries temporais em estudos epidemiol\u00f3gicos. Epidemiol Serv Sa\u00fade. 2015 Sep;24(3):565-76. https://doi.org/10.5123/S1679-49742015000300024\n[\u00bb https://doi.org/10.5123/S1679-49742015000300024](https://doi.org/10.5123/S1679-49742015000300024)\n-\n16Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348-55. https://doi.org/10.1093/ije/dyw098\n[\u00bb https://doi.org/10.1093/ije/dyw098](https://doi.org/10.1093/ije/dyw098)\n-\n17Novoa PCR. What changes in Research Ethics in Brazil: Resolution no. 466/12 of the National Health Council. Einstein (S\u00e3o Paulo). 2014;12(1). https://doi.org/10.1590/S1679-45082014ED3077\n[\u00bb https://doi.org/10.1590/S1679-45082014ED3077](https://doi.org/10.1590/S1679-45082014ED3077)\n-\n18Patel C, Brotherton JML, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41):30-40. https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737\n[\u00bb https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737](https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737)\n-\n19Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters. 2008;16(32):97-103. https://doi.org/10.1016/S0968-8080(08)32413-6\n[\u00bb https://doi.org/10.1016/S0968-8080(08)32413-6](https://doi.org/10.1016/S0968-8080(08)32413-6)\n-\n20Silva TMR, S\u00e1 ACMGN, Beinner MA, Abreu MNS, Matozinhos FP, Sato APS, et al. Impact of the COVID-19 Pandemic on Human Papillomavirus Vaccination in Brazil. Int J Public Health. 2022;(39). https://doi.org/10.3389/ijph.2022.1604224\n[\u00bb https://doi.org/10.3389/ijph.2022.1604224](https://doi.org/10.3389/ijph.2022.1604224)\n-\n21Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17(2):400-7. https://doi.org/10.1080/21645515.2020.1804776\n[\u00bb https://doi.org/10.1080/21645515.2020.1804776](https://doi.org/10.1080/21645515.2020.1804776)\n-\n22Bruni L, Saura-L\u00e1zaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med (Baltimore). 2021 Mar 1;144:106399. https://doi.org/10.1016/j.ypmed.2020.106399\n[\u00bb https://doi.org/10.1016/j.ypmed.2020.106399](https://doi.org/10.1016/j.ypmed.2020.106399)\n-\n23LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821. https://doi.org/10.2471/BLT.11.089862\n[\u00bb https://doi.org/10.2471/BLT.11.089862](https://doi.org/10.2471/BLT.11.089862)\n-\n24Pinto AFR, Rocha LEV. Evolu\u00e7\u00e3o e Din\u00e2mica Territorial da Criminalidade Violenta no Estado de Minas Gerais [Internet]. 2022 [cited 2022 Apr 22]. Available from: Available from: https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf\n[\u00bb https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf](https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf)\n-\n25Dub\u00e9 E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy-country-specific characteristics of a global phenomenon. Vaccine. 2014;32(49):6649-54. https://doi.org/10.1016/j.vaccine.2014.09.039\n[\u00bb https://doi.org/10.1016/j.vaccine.2014.09.039](https://doi.org/10.1016/j.vaccine.2014.09.039)\n-\n26Silva LOL, Dias CA, Soares MM, Rodrigues SM. Acessibilidade ao servi\u00e7o de sa\u00fade: percep\u00e7\u00f5es de usu\u00e1rios e profissionais de sa\u00fade. Cogitare Enferm. 2011;16(4). https://doi.org/10.5380/ce.v16i4.25434\n[\u00bb https://doi.org/10.5380/ce.v16i4.25434](https://doi.org/10.5380/ce.v16i4.25434)\n-\n27Elizondo-Alzola U, Carrasco MG, Pin\u00f3s L, Picchio CA, Riuss C, Diez E. Vaccine hesitancy among paediatric nurses: Prevalence and associated factors. PloS One. 2021;16(5):e0251735. https://doi.org/10.1371/journal.pone.0251735\n[\u00bb https://doi.org/10.1371/journal.pone.0251735](https://doi.org/10.1371/journal.pone.0251735)\n-\n*\nThis article refers to the call \u201cAdolescent health and the role of nurses\u201d. Edited by Universidade de S\u00e3o Paulo, Escola de Enfermagem de Ribeir\u00e3o Preto, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeir\u00e3o Preto, SP, Brazil. Publication of this supplement was supported by the Pan American Health Organization (PAHO/WHO). Articles have undergone the journal\u2019s standard peer-review process for supplements. The views expressed in this supplement are those of the authors alone and do not represent the views of PAHO/WHO.\nEdited by\n-\nAssociate Editor: Ricardo Alexandre Arc\u00eancio\nPublication Dates\n-\nPublication in this collection\n25 Nov 2022\n-\nDate of issue\n2022\nHistory\n-\nReceived\n19 May 2022\n-\nAccepted\n15 Aug 2022", "language": null, "image": "https://www.scielo.br/media/images/rlae_glogo.gif", "pagetype": "article", "links": [null, "#", "/", "/journals/alpha?status=current", "/journals/thematic?status=current", "//search.scielo.org/?q=*&lang=pt&filter[in][]=scl", "http://analytics.scielo.org/?collection=scl", "/about/", "/about/", "//www.scielo.org", "//www.scielo.org", "//www.scielo.org/pt/periodicos/listar-por-ordem-alfabetica/", "//www.scielo.org/pt/periodicos/listar-por-assunto/", "//search.scielo.org/", "http://analytics.scielo.org", "//www.scielo.org/pt/sobre-o-scielo/acesso-via-oai-e-rss/", "//www.scielo.org/pt/sobre-o-scielo/", "//www.scielo.org/pt/sobre-o-scielo/contato/", "//blog.scielo.org", "", "/", "", "/j/rlae/", "http://mc04.manuscriptcentral.com/rlae-scielo", "/journal/rlae/about/#about", "/journal/rlae/about/#editors", "/journal/rlae/about/#instructions", "/journal/rlae/about/#contact", "/set_locale/es/", "/set_locale/en/", "", "/", "/set_locale/es/", "/set_locale/en/", "", "/j/rlae/", "http://mc04.manuscriptcentral.com/rlae-scielo", "/journal/rlae/about/#about", "/journal/rlae/about/#editors", "/journal/rlae/about/#instructions", "/journal/rlae/about/#contact", "/j/rlae/", "/j/rlae/i/2022.v30nspe/", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=en&goto=previous", "#", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=en&goto=next", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/abstract/?lang=en", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/abstract/?lang=pt", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/abstract/?lang=es", "#", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=es", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=pt", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?format=pdf&lang=en", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?format=pdf&lang=pt", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?format=pdf&lang=es", "javascript:;", "#", "#", "#", "#", "#", "#", "#", "#", "#", "/j/rlae/", "/j/rlae/i/2022.v30nspe/", "javascript:;", "#", "#", "#", "#", "#", "#", "#", "#", "#", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/abstract/?lang=en", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/abstract/?lang=pt", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/abstract/?lang=es", "#", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=es", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=pt", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?format=pdf&lang=en", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?format=pdf&lang=pt", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?format=pdf&lang=es", "https://doi.org/10.1590/1518-8345.6285.3804", null, "#", "", "", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf", "https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://doi.org/10.24302/sma.v6i2.1528", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.1186/s12889-016-2845-z", "https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy", "https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy", "https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1590/1980-549720210001", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1590/1980-549720210001", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1590/1980-549720210001", "https://doi.org/10.1007/s10900-018-0565-2", "https://doi.org/10.1590/1413-81232017224.26392016", "http://sipni.datasus.gov.br/si-pni-web/faces/inicio.jsf", "http://atlasbrasil.org.br/consulta/planilha", "http://www.seguranca.mg.gov.br/2018-08-22-13-39-06/dados-abertos", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1590/1980-549720210001", "https://doi.org/10.1007/s10900-018-0565-2", null, "https://doi.org/10.1590/S1679-45082014ED3077", "", null, null, "", null, null, "", null, null, "", null, null, "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org/10.1016/S0968-8080(08)32413-6", "https://doi.org/10.1016/j.canlet.2019.11.039", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org/10.3389/ijph.2022.1604224", "https://doi.org/10.3389/ijph.2022.1604224", "https://doi.org/10.1080/21645515.2020.1804776", "https://doi.org/10.1016/j.ypmed.2020.106399", "https://doi.org/10.2471/BLT.11.089862", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org/10.2471/BLT.11.089862", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1186/s12889-016-2845-z", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org/10.1016/S0968-8080(08)32413-6", "https://doi.org/10.1016/j.ypmed.2020.106399", "https://doi.org/10.2471/BLT.11.089862", "https://doi.org/10.2471/BLT.11.089862", "https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf", "https://doi.org/10.1016/j.vaccine.2014.09.039", "https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf", "https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy", "https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf", "https://doi.org/10.1016/j.vaccine.2014.09.039", "https://doi.org/10.5380/ce.v16i4.25434", "https://doi.org/10.1371/journal.pone.0251735", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org/10.1016/S0968-8080(08)32413-6", "https://doi.org/10.2471/BLT.11.089862", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1371/journal.pone.0251735", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1371/journal.pone.0251735", "https://doi.org/10.1080/21645515.2020.1804776", "https://doi.org/10.1016/j.canlet.2019.11.039", "https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf", "https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind", "https://sbim.org.br/images/files/notas-tecnicas/vacina-hpv-crie-45-anos.pdf", "http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=2m3JjlW6qoI%3D", "https://doi.org/10.24302/sma.v6i2.1528", "https://doi.org/10.37689/acta-ape/2022AO02291", "https://doi.org/10.1186/s12889-016-2845-z", "https://www.comminit.com/polio/content/appendices-report-sage-working-group-vaccine-hesitancy", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1097/NNR.0000000000000413", "https://doi.org/10.1590/1980-549720210001", "https://doi.org/10.1007/s10900-018-0565-2", "https://doi.org/10.1590/1413-81232017224.26392016", "https://doi.org/10.5123/S1679-49742015000300024", "https://doi.org/10.1093/ije/dyw098", "https://doi.org/10.1590/S1679-45082014ED3077", "https://doi.org10.2807/1560-7917.ES.2018.23.41.1700737", "https://doi.org/10.1016/S0968-8080(08)32413-6", "https://doi.org/10.3389/ijph.2022.1604224", "https://doi.org/10.1080/21645515.2020.1804776", "https://doi.org/10.1016/j.ypmed.2020.106399", "https://doi.org/10.2471/BLT.11.089862", "https://brsa.org.br/wp-content/uploads/wpcf7-submissions/4554/artigo-amanda-enaber-1.pdf", "https://doi.org/10.1016/j.vaccine.2014.09.039", "https://doi.org/10.5380/ce.v16i4.25434", "https://doi.org/10.1371/journal.pone.0251735", "https://creativecommons.org/licenses/by/4.0/", "https://creativecommons.org/licenses/by/4.0/", "", "http://orcid.org/0000-0002-6093-2956", "", "http://orcid.org/0000-0002-7115-0925", "", "http://orcid.org/0000-0002-5261-2266", "", "http://orcid.org/0000-0002-3323-5776", "", "http://orcid.org/0000-0002-4017-4772", "", "http://orcid.org/0000-0003-1368-4248", "mailto:nandapenido@hotmail.com", "", "#tables", "#schemes", null, null, null, null, null, null, "#top", "javascript:;", "javascript:;", "javascript:;", null, null, null, null, "javascript:;", "#top", "#", "#", "#", "#", "#", "#", "/journal/rlae/feed/", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=en&format=pdf", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=pt&format=pdf", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=es&format=pdf", "https://www.google.com/search?q=\"Environmental factors associated with human papillomavirus vaccine coverage in adolescents: 2016-2020 analysis\" \"Luvisaro, Bianca Maria Oliveira\" \"Silva, Thales Philipe Rodrigues da\" \"Silva, Tercia Moreira Ribeiro da\" \"Lachtim, Sheila Aparecida Ferreira\" \"Souza, Janaina Fonseca Almeida\" \"Matozinhos, Fernanda Penido\" \"2022\" \"Revista Latino-Americana de Enfermagem\"", "https://scholar.google.com/scholar?q=\"Environmental factors associated with human papillomavirus vaccine coverage in adolescents: 2016-2020 analysis\" \"Luvisaro, Bianca Maria Oliveira\" \"Silva, Thales Philipe Rodrigues da\" \"Silva, Tercia Moreira Ribeiro da\" \"Lachtim, Sheila Aparecida Ferreira\" \"Souza, Janaina Fonseca Almeida\" \"Matozinhos, Fernanda Penido\" \"2022\" \"Revista Latino-Americana de Enfermagem\"", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=en", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=es", "/j/rlae/a/PdMhv8Gt6q9d7P6jNGHhYQw/?lang=pt", "", "", "/citation/export/PdMhv8Gt6q9d7P6jNGHhYQw/?format=ris", "/citation/export/PdMhv8Gt6q9d7P6jNGHhYQw/?format=bib", "http://www.fapesp.br/", "http://www.capes.gov.br/", "http://www.cnpq.br/", "http://bvsalud.org/", "http://regional.bvsalud.org/bvs/bireme/homepage.htm", "https://www.fapunifesp.edu.br/", "/about/", "http://analytics.scielo.org/w/accesses?document=S0104-11692022000200222&collection=scl", "https://badge.dimensions.ai/details/doi/10.1590/1518-8345.6285.3804", "https://www.altmetric.com/details.php?&doi=10.1590/1518-8345.6285.3804", "https://scite.ai/reports/10.1590/1518-8345.6285.3804", "https://plu.mx/scielo/a/?doi=10.1590/1518-8345.6285.3804", "https://plu.mx/scielo/a/?doi=10.1590/1518-8345.6285.3804"]}